Market Research Reports

Pain Management Therapeutics Market (Anticonvulsants, Antidepressants, Anesthetics, NSAIDs, Opioids, Other Non-Narcotic Analgesics and Anti-Migraine Agents) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018

155pages
Published Date: 2013-07-31
 

Description


The global pain management therapeutics market is expected to witness a decline during the forecast period (2012 to 2018) due to patent expirations of the key blockbuster revenue generating drugs such as Cymbalta (duloxetine) of Eli Lilly & Co. and Lyrica (pregabalin) of Pfizer, Inc. This report studies the global market for pain management therapeutics from three perspectives - therapeutic classes of drugs, indications and geography. Each of these segments is further classified into sub-segments; therapeutic classes include anticonvulsants, antidepressants, anesthetics, NSAIDs, opioids, anti-migraine agents and other non-narcotic analgesics. 

The various pain management indications studied in this report include neuropathic pain, fibromyalgia, arthritic pain, chronic back pain, migraine, post-operative pain and cancer pain. Market sizes and forecasts for the period 2010 – 2018 have been provided for each of the segments and sub-segments in terms of USD million, considering 2011 as the base year. The % compound annual growth rate (CAGR) for each market segment for the forecast period (2012 to 2018) has been provided along with market size estimations.

Geographically, the market has been segmented into four regions, namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). The respective market sizes and forecasts have been provided for each of these regions along with the CAGR. The market overview section of the report provides a detailed breakdown of various aspects of market dynamics such as drivers, restraints and opportunities along with market attractiveness analysis and Porter’s five force analysis for the pain management therapeutics market.

The competitive landscape section includes market share analysis of all the leading players in the branded pharmaceuticals market for pain management, in terms of percentage share in the year 2011. Some of the major players profiled in this report include Abbott Laboratories, Inc., AstraZeneca PLC, Eli Lilly & Co., Endo Health Solutions, Johnson & Johnson, Merck & Co., Inc., Pfizer, Inc. and Purdue Pharma LP.

The global pain management market is segmented into the following categories:

Pain Management Therapeutics Market, by Therapeutic Class
  • Anticonvulsants
  • Antidepressants
  • Anesthetics
  • NSAIDs
  • Opioids
  • Other Non-Narcotic Analgesics (Acetaminophen)
  • Anti-Migraine Agents
Pain Management Therapeutics Market, by Indication
  • Neuropathic Pain
  • Fibromyalgia
  • Arthritic Pain, by Type
    • Osteoarthritis
    • Rheumatoid Arthritis
  • Chronic Back Pain
  • Migraine
  • Post-operative Pain
  • Cancer Pain
Pain Management Therapeutics Market, by Geography
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World (RoW)

Table of Contents


Table of Content

Chapter 1 Preface
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology

Chapter 2 Executive Summary

Chapter 3 Market Overview
3.1 Introduction to Pain Management – Types of Treatments
3.2 World Health Organization’s “Pain Ladder” for cancer
3.3 Market Trends and Future Outlook
       3.3.1 Impact of generics
       3.3.2 Key patent expirations
3.4 Market Drivers
       3.4.1 Global increasing incidence of chronic pain disorders
       3.4.2 Favorable regulatory scenario and healthcare reforms
       3.4.3 Easy and effective medications
       3.4.4 Impact analysis of market drivers
3.5 Market Restraints
       3.5.1 Prescription drug abuse
       3.5.2 Pain advocacy groups losing power, influence and funding
       3.5.3 Adulteration and fake drugs thrive in developing regions
       3.5.4 Long term pain relief from surgical procedures, alternative therapies and medical devices
       3.5.5 Impact analysis of market restraints
3.6 Market Opportunities
       3.6.1 Novel molecule combinations and drug delivery techniques are expected to become a rising opportunity in forecast period
       3.6.2 Generics expected to be a rising opportunity globally
3.7 Porter’s Five Forces Analysis
       3.7.1 Bargaining power of buyers
       3.7.2 Bargaining power of suppliers
       3.7.3 Threat of substitutes
       3.7.4 Threat of new entrants
       3.7.5 Competitive rivalry
3.8 Market Attractiveness Analysis: Global Pain Management Therapeutics Market, By Geography (2011)

Chapter 4 Global Pain Management Therapeutics Market, by Therapeutic Class
4.1 Anticonvulsants
       4.1.1 Current and future market scenario
4.2 Antidepressants
       4.2.1 Current market scenario and patent expiry effect
       4.2.2 Future market scenario
4.3 Anesthetics
       4.3.1 Current market scenario and patent expiry effect
       4.3.2 Pipeline drugs and their effect
       4.3.3 General Anesthetics
       4.3.4 Local Anesthetics
4.4 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
       4.4.1 Current market scenario and patent expiry effect
4.5 Opioids
       4.5.1 Current market scenario and patent expiry effect
       4.5.2 Pipeline drugs and their effect on the market
                4.5.2.1 MoxDuo IR
                4.5.2.2 Remoxy
4.6 Anti-Migraine Agents
       4.6.1 Pipeline drugs and additional approvals
4.7 Other Non-Narcotic Analgesics (Acetaminophen)

Chapter 5 Global Pain Management Therapeutics Market, by Indication
5.1 Neuropathic Pain
5.2 Fibromyalgia
5.3 Arthritic Pain
       5.3.1 Osteoarthritis (OA)
       5.3.2 Rheumatoid Arthritis (RA)
5.4 Chronic Back Pain
5.5 Migraine
5.6 Post-operative pain
5.7 Cancer Pain

Chapter 6 Global Pain Management Therapeutics Market, by Geography
6.1 Overview
       6.1.1 Global Pain Management Therapeutics Market, by Geography, Size and Forecast, 2010 – 2018 (USD Million)
       6.1.2 Comparative Analysis: Global Pain Management Therapeutics Market, by Geography, 2011 & 2018 (Value %)
6.2 North America
       6.2.1 North America Pain Management Therapeutics  Market, by Therapeutic Class, Size and Forecast, 2010 - 2018 (USD Million)
6.3 Europe
       6.3.1 Europe Pain Management Therapeutics  Market, by Therapeutic Class, Size and Forecast, 2010 - 2018 (USD Million)
6.4 Asia-Pacific
       6.4.1 Asia-Pacific Pain Management Therapeutics  Market, by Therapeutic Class, Size and Forecast, 2010 - 2018 (USD Million)
6.5 Rest of the World (RoW)
       6.5.1 RoW Pain Management Therapeutics Market, by Therapeutic Class, Size and 
Forecast, 2010 - 2018 (USD Million)

Chapter 7 Competitive Landscape
7.1 Market Share Analysis: Global Pain Management Therapeutics Market (2011)
       7.1.1 Market Share by Marketing Status (Branded & Generic Pharmaceuticals), 2011 (%)
       7.1.2 Market Share by Key Players: Branded Pharmaceuticals, 2011 (%)
7.2 Pipeline Snapshot: Pain Management Therapeutics
       7.2.1 MoxDuo (morphine and oxycodone)
       7.2.2 Remoxy (oxycodone)
       7.2.3 Posidur (SABER-bupivacaine)
       7.2.4 Zecuity (transdermal sumatriptan)

Chapter 8 Recommendations
8.1 Development of novel combination formulations
8.2 Addressing unmet needs: drug abuse and side-effects
8.3 Generics manufacturers: Investment in emerging markets such as India, China and Russia
8.4 Mergers and acquisitions to enter or strengthen market presence

Chapter 9 Company Profiles
9.1 Abbott Laboratories
       9.1.1 Company Overview
       9.1.2 Financial Overview
       9.1.3 Product Portfolio
       9.1.4 Business Strategies
       9.1.5 Recent Developments
9.2 Allergan, Inc.
       9.2.1 Company Overview
       9.2.2 Financial Overview
       9.2.3 Product Portfolio
       9.2.4 Business Strategies
       9.2.5 Recent Developments
9.3 Covidien plc
       9.3.1 Company Overview
       9.3.2 Financial Overview
       9.3.3 Product Portfolio
       9.3.4 Business Strategies
       9.3.5 Recent Developments
9.4 Durect Corporation
       9.4.1 Company Overview
       9.4.2 Financial Overview
       9.4.3 Pipeline Products
       9.4.4 Business Strategies
       9.4.5 Recent Developments
9.5 Eli Lilly and Company
       9.5.1 Business Overview
       9.5.2 Financial Overview
       9.5.3 Product Portfolio
       9.5.4 Business Strategies
       9.5.5 Recent Developments
9.6 Endo Health Solutions, Inc.
       9.6.1 Company Overview
       9.6.2 Financial Overview
       9.6.3 Product Portfolio
       9.6.4 Business Strategies
       9.6.5 Recent Developments
9.7 Forest Laboratories, Inc.
       9.7.1 Company Overview
       9.7.2 Financial Overview
       9.7.3 Product Portfolio
       9.7.4 Business Strategies
       9.7.5 Recent Developments
9.8 GlaxoSmithKline plc
       9.8.1 Company Overview
       9.8.2 Financial Overview
       9.8.3 Product Portfolio
       9.8.4 Business Strategies
       9.8.5 Recent Developments
9.9 Hospira, Inc.
       9.9.1 Company Overview
       9.9.2 Financial Overview
       9.9.3 Product Portfolio
       9.9.4 Business Strategies
       9.9.5 Recent Developments
9.10 Johnson & Johnson
       9.10.1 Company Overview
       9.10.2 Financial Overview
       9.10.3 Product Portfolio
       9.10.4 Business Strategies
       9.10.5 Recent Developments
9.11 Merck & Co., Inc.
       9.11.1 Company Overview
       9.11.2 Financial Overview
       9.11.3 Product Portfolio
       9.11.4 Business Strategies
       9.11.5 Recent Developments
9.12 Mundipharma International Ltd.
       9.12.1 Company Overview
       9.12.2 Financial Overview
       9.12.3 Product Portfolio
       9.12.4 Business Strategies
       9.12.5 Recent Developments
9.13 Novartis  International AG
       9.13.1 Company Overview
       9.13.2 Financial Overview
       9.13.3 Product Portfolio
       9.13.4 Business Strategies
       9.13.5 Recent Developments
9.14 NuPathe, Inc.
       9.14.1 Company Overview
       9.14.2 Financial Overview
       9.14.3 Product Portfolio
       9.14.4 Business Strategies
       9.14.5 Recent Developments
9.15 Pain Therapeutics, Inc.
       9.15.1 Company Overview
       9.15.2 Financial Overview
       9.15.3 Product Portfolio
       9.15.4 Business Strategies
       9.15.5 Recent Developments
9.16 Pfizer, Inc.
       9.16.1 Company Overview
       9.16.2 Financial Overview
       9.16.3 Product Portfolio
       9.16.4 Business Strategies
       9.16.5 Recent Developments
9.17 Purdue Pharma L.P.
       9.17.1 Company Overview
       9.17.2 Financial Overview
       9.17.3 Product Portfolio
       9.17.4 Business Strategies
       9.17.5 Recent Developments
9.18 QRx Pharma Ltd.
       9.18.1 Company Overview
       9.18.2 Financial Overview
       9.18.3 Product Portfolio
       9.18.4 Business Strategies
       9.18.5 Recent Developments
9.19 Sanofi
       9.19.1 Company Overview
       9.19.2 Financial Overview
       9.19.3 Product Portfolio
       9.19.4 Business Strategies
       9.19.5 Recent Developments
9.20 Teva Pharmaceutical Industries Limited
       9.20.1 Company Overview
       9.20.2 Financial Overview
       9.20.3 Product Portfolio
       9.20.4 Business Strategies
       9.20.5 Recent Developments
9.21 UCB (Union Chemnique Belge) S.A.
       9.21.1 Company Overview
       9.21.2 Financial Overview
       9.21.3 Product Portfolio
       9.21.4 Business Strategies
       9.21.5 Recent Developments

List of Figures

FIG. 1 Pain Management Therapeutics Market Segmentation
FIG. 2 Global Pain Management Therapeutics Market, by Therapeutic Class, 2011 (USD Million)
FIG. 3 Global Pain Management Therapeutics Market, by Indication, 2011 (USD Million)
FIG. 4 Porter’s Five Forces Analysis: Global Pain Management Therapeutics Market
FIG. 5 Market Attractiveness Analysis: Global Pain Management Therapeutics Market, By Geography (2011)
FIG. 6 Global Anticonvulsants Market for Pain Management, 2010 – 2018 (USD Million)
FIG. 7 Global Antidepressants Market for Pain Management, 2010 – 2018 (USD Million)
FIG. 8 Global Antidepressants Market for Pain Management, 2010 – 2015 (USD Million)
FIG. 9 Global Antidepressants Market for Pain Management, 2015 – 2018 (USD Million)
FIG. 10 Global Anesthetics Market, 2010 – 2018 (USD Million)
FIG. 11 Global Anesthetics Market, 2010 – 2015 (USD Million)
FIG. 12 Global Anesthetics Market, 2015 – 2018 (USD Million)
FIG. 13 Global General Anesthetics Market, 2010 – 2018 (USD Million)
FIG. 14 Global Local Anesthetics Market, 2010 – 2018 (USD Million)
FIG. 15 Global Non-Steroidal Anti-Inflammatory Drugs Market, 2010 – 2018 (USD Million)
FIG. 16 Global Opioids Market, 2010 – 2018 (USD Million)
FIG. 17 Global Opioids Market, 2010 – 2015 (USD Million)
FIG. 18 Global Opioids Market, 2015 – 2018 (USD Million)
FIG. 19 Global Anti-Migraine Agents Market, 2010 – 2018 (USD Million)
FIG. 20 Global Anti-Migraine Agents Market, 2015 – 2018 (USD Million)
FIG. 21 Global Other Non-Narcotic Analgesics Market, 2010 – 2018 (USD Million)
FIG. 22 Global Neuropathic Pain Market, 2010 – 2018 (USD Million)
FIG. 23 Global Fibromyalgia Market, 2010 – 2018 (USD Million)
FIG. 24 Global Arthritic Pain Market, 2010 – 2018 (USD Million)
FIG. 25 Global Chronic Back Pain Market, 2010 – 2018 (USD Million)
FIG. 26 Global Migraine Market, 2010 – 2018 (USD Million)
FIG. 27 Global Post-operative Pain Market, 2010 – 2018 (USD Million)
FIG. 28 Global Cancer Pain Market, 2010 – 2018 (USD Million)
FIG. 29 Comparative Analysis: Global Pain Management Therapeutics Market, by Geography, 2011 & 2018 (Value %)
FIG. 30 North America Pain Management Therapeutics Market, 2010 – 2018 (USD Million)
FIG. 31 Europe Pain Management Market, 2010 – 2018 (USD Million)
FIG. 32 Asia-Pacific Pain Management Therapeutics Market, 2010 – 2018 (USD Million)
FIG. 33 RoW Pain Management Therapeutics Market, 2010 – 2018 (USD Million)
FIG. 34 Market Share by Marketing Status (Branded & Generic Pharmaceuticals), 2011 (%)
FIG. 35 Market Share by Key Players: Branded Pharmaceuticals, 2011 (%)
FIG. 36 Posidur Vs Others: A Comparison of Pain Relief Duration
FIG. 37 Annual Revenues: Abbott Laboratories,  2010 – 2012 (USD million)
FIG. 38 Annual Revenues: Allergan, Inc.,  2010 - 2012 (USD million)
FIG. 39 Annual Revenues: Covidien plc,  2010 – 2012 (USD million)
FIG. 40 Annual Revenues: Durect Corporation.,  2010 -2012 (USD million)
FIG. 41 Annual Revenues: Eli Lilly and Company,  2010 – 2012 (USD million)
FIG. 42 Annual Revenues: Endo Health Solutions, Inc.,  2010 – 2012 (USD million)
FIG. 43 Annual Revenues: Forest Laboratories, Inc.,  2010 – 2012 (USD million)
FIG. 44 Annual Revenues: GlaxoSmithKline plc,  2010 – 2012 (USD million)
FIG. 45 Annual Revenues: Hospira, Inc.,  2010 – 2012 (USD million)
FIG. 46 Annual Revenues: Johnson & Johnson,  2010 – 2012 (USD million)
FIG. 47 Annual Sales: Merck & Co.,  2010 – 2012 (USD million)
FIG. 48 Annual Revenues: Novartis  international AG ,  2010 – 2012 (USD million)
FIG. 49 Annual Revenues: Pain Therapeutics, Inc.,  2010 - 2012 (USD million)
FIG. 50 Annual Revenues: Pfizer, Inc., 2010 – 2012 (USD million)
FIG. 51 Annual Revenues: QRx Pharma Ltd.,  2010 - 2012 (USD million)
FIG. 52 Annual Sales: Sanofi, 2010 – 2012 (USD million)
FIG. 53 Annual Revenues: Teva Pharmaceutical Industries Limited,  2010 – 2012 (USD million)
FIG. 54 Annual Revenues: UCB,  S.A., 2010 – 2012 (USD million)

List of Tables

TABLE 1 Market Snapshot: Global Pain Management Therapeutics Market
TABLE 2 Impact Analysis of Market Drivers
TABLE 3 Impact Analysis of Market Restraints
TABLE 4 Global Anesthetics Market, by Segments, 2010 – 2018 (USD Million)
TABLE 5 Licensed Pharmaceuticals for Neuropathic Pain Management
TABLE 6 Key Licensed Pharmaceuticals for Arthritic Pain Management
TABLE 7 Global Pain Management Therapeutics Market, by Geography, Size and Forecast, 2010 – 2018 (USD Million)
TABLE 8 North America Pain Management Therapeutics Market, by Therapeutic Class, Size and Forecast, 2010 - 2018 (USD Million)
TABLE 9 Europe Pain Management Therapeutics Market, by Therapeutic Class, Size and Forecast, 2010 - 2018 (USD Million)
TABLE 10 Asia-Pacific Pain Management Therapeutics Market, by Therapeutic Class, Size and Forecast, 2010 - 2018 (USD Million)
TABLE 11 RoW Pain Management Therapeutics Market, by Therapeutic Class, Size and Forecast, 2010 - 2018 (USD Million)

Enquiry Before Buying


Free Market Analysis


Pain usually results from tissue damage and the severity of pain differs from person to person. Pain can be classified on the basis of the duration and pattern of occurrence along with the affected body part. Pain management aims at alleviating pain and improving the quality of life of the patients suffering from acute or chronic pain disorders. It is one of the major health concerns across the globe due to its debilitating effects and loss of productivity. Presently, various methods of pain management are available such as the use of minimally invasive pain management devices, physiotherapy and chiropractor therapy. However, pharmaceuticals that are commonly called analgesics or painkillers form the first line of treatment prescribed by the physicians. These include drugs belonging to various therapeutic classes such as anticonvulsants, antidepressants, opioids, non-steroidal anti-inflammatory drugs (NSAIDs), anti-migraine agents and others. The demand for pain management is high and growing in order to cater to the needs of rising number of patients with chronic pain disorders. These pain conditions in turn affect their productivity and increase the nation’s healthcare expenditure on pain management.

The pain management therapeutics market is expected to witness a decline globally in the next five years due to patent expirations of the key blockbuster revenue generating drugs such as Cymbalta (duloxetine) of Eli Lilly & Co. and Lyrica (pregabalin) of Pfizer, Inc. The loss of patent and marketing exclusivity will lead to a drastic reduction in revenues and in turn provide an opportunity to generic manufacturers to launch their own versions of these brands. In addition to this, lack of novel drug formulations in pain management will also account for the dip in the growth of the overall pain management drugs market.

The NSAIDs segment was the largest revenue generator in 2011 of the total market, owing to the presence of the most commonly used OTC painkillers such as diclofenac, ibuprofen and Aspirin (acetylsalicylic acid). By indication, cancer pain and neuropathic pain were the two largest segments in 2011 of the total pain management therapeutics market due to the rising incidence rates globally of conditions such as cancer and diabetes.

The North American market for pain management therapeutics was valued at USD 21,733.3 million in the year 2011 and is expected to decline to USD 14,264.3 million by 2018, although the region is expected to continue to lead the market in terms of revenue throughout the forecast period. In terms of market growth and attractiveness, Asia-Pacific and Rest of the World (RoW) are considered the most lucrative markets for pain management drugs due to rigorous government initiatives and healthcare amendments favoring the expansion of this market. The continuous economic slowdown in Europe will further decelerate its growth and the region’s contribution to the overall market is expected to remain constant throughout the forecast period. Some of the leading players in the market for branded pain management therapeutics include Pfizer, Inc., Purdue Pharma L.P., Endo Health Solutions, Eli Lilly & Co., Johnson & Johnson and AstraZeneca PLC.

global-pain-management-therapeutics-market-by-therapeutic-class-2011
 

To get discount on this report, just click on the button below.

To receive brochure, please click on the button below.

Share This Market Study!  

Upcoming Report

Payment
Copyright @ Transparency Market Research